Precision BioSciences Appoints New CMO, Director

TL;DR

Precision BioSciences brings in a new CMO and board member, potentially signaling a new direction.

AI Summary

Precision BioSciences, Inc. announced on September 9, 2024, the appointment of Dr. Michael A. Caligiuri as Chief Medical Officer and the election of Dr. Sarah E. Michaels to its Board of Directors. The company also disclosed compensatory arrangements for certain officers, details of which are filed as exhibits.

Why It Matters

The appointment of a new Chief Medical Officer and a new board member could signal strategic shifts in the company's research and development or corporate governance.

Risk Assessment

Risk Level: medium — Changes in key leadership and board composition can indicate strategic shifts or internal challenges, warranting closer observation.

Key Players & Entities

• Precision BioSciences, Inc. (company) — Registrant
• Dr. Michael A. Caligiuri (person) — Appointed Chief Medical Officer
• Dr. Sarah E. Michaels (person) — Elected to Board of Directors
• September 9, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.000005 — ch registered Common Stock, par value $0.000005 per share DTIL The Nasdaq Capital M
• $325 — ces to the Company for an hourly fee of $325 per hour. The Consulting Agreement also

Filing Documents

• dtil-20240909.htm (8-K) — 55KB
• dtil-ex99_1.htm (EX-99.1) — 30KB
• 0000950170-24-105706.txt ( ) — 213KB
• dtil-20240909.xsd (EX-101.SCH) — 27KB
• dtil-20240909_htm.xml (XML) — 5KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 12, 2024, the Company issued a press release announcing Dr. List's retirement in addition to the appointment of Dr. Murray Abramson, M.D., M.P.H. as Senior Vice President, Head of Clinical Development and John Fry as Strategic Clinical Advisor, specializing in hepatits, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, expectations regarding Dr. List's entering into the Consulting Agreement and Dr. List's performance under the Consulting Agreement. In some cases, you can identify forward-looking statements by terms such as "aim," "anticipate," "approach," "believe," "contemplate," "could," "designed", "estimate," "expect," "goal," "intend," "look," "may," "mission," "plan," "possible," "potential," "predict," "project," "pursue," "should,", "strive", "target," "will," "would," or the negative thereof and similar words and expressions. Forward-looking statements are based on management's current expectations, beliefs and assumptions and on information currently available to us. Such statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including the risks identified from time to time in the reports the Company files with the Securities and Exchange Commission ("SEC"), including the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, as such factors may be updated from time to time in its other filings with the SEC, accessible on the SEC's website at www.sec.gov . The forward-looking statements in this Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K, and th

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Precision BioSciences, Inc. dated September 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRECISION BIOSCIENCES, INC. Date: September 12, 2024 By: /s/ Dario Scimeca Dario Scimeca General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR